

## **2010/11 Adult Preventive Care Recommendations**

| Health<br>Maintenance Visit   | 18–29 Years  | 30–39 Years                                   | 40-49 Years  | 50-64 Years  | 65 + Years  |  |  |
|---|--|---|--|--|---|--|--|
| Includes initial/<br>interval history, age-<br>appropriate physical<br>exam; preventive<br>screenings and<br>counseling; assessment<br>and administration of<br>needed immunizations. | Annually for ages 18-21.  Every 1-3 years depending on risk factors.   | Every 1-3 years depending<br>on risk factors. | Every 1-3 years depending on risk factors.   | Annually.  | Annually.   |  |  |
| Cancer Screening  |  |   |  |  |   |  |  |
| Breast Cancer   | Starting at age 20, clinical br<br>on benefits and limitations o<br>Mammography for patients of  | f self-exam instruction.                      | Clinical breast exam and counsel on benefits and limitations of self-exam instruction. Conduct mammography every two years at discretion of clinician/patient. | Clinical breast exam and counsel on benefits and limitations of self-exam instruction. Conduct mammography every two years.  | Clinical breast exam and counsel on benefits and limitations of self-exam instruction. Conduct mammography every two years through age 74; $\geq$ 75 at clinician/patient discretion. |  |  |
| Cervical Cancer (Pap Test<br>and Pelvic Exam)   | Initiate Pap test and pelvic<br>exam at age 21, or earlier<br>at physician/patient<br>discretion. Perform every<br>two years through age 29.                     | Perform every 1-3 years at cl                 | inician discretion.  |  |   |  |  |
| Colorectal Cancer   | Not routine except for patier  | ts at high risk.                              |  | Colonoscopy at age 50 and then every 10 years,<br>or annual fecal occult blood test (FOBT) plus<br>sigmoidoscopy every 5 years, or annual FOBT. Screening<br>after age 75 at clinician/patient discretion. |   |  |  |
| Testicular Cancer   | Clinical testicular exam and oinstruction.   | counsel on benefits and limita                | ations of self-exam  |  |   |  |  |
| Prostate Cancer   |  |   |  | Digital rectal exam (DRE) for patients at high risk for prostate cancer. Offer PSA screening at clinician/ patient discretion.   |   |  |  |
| Skin Cancer   | Periodic total skin exams every 3 years between the ages of 20 and 39 and annually at age 40 and older. Frequency at clinician discretion based on risk factors. |   |  |  |   |  |  |
| Other Recommended S   | creening   |   |  |  |   |  |  |
| Body Mass Index (BMI)   | Screen for obesity. Consult the CDC's growth and BMI charts (www.cdc.gov/nccdphp/dnpa/bmi/index.htm). Ask about body image and dieting patterns.                 |   |  |  |   |  |  |
| Hypertension  | At every acute/nonacute medical encounter and at least once every 2 years.   |   |  |  |   |  |  |
| Cholesterol   | Screen if not previously tested. Screen every 5 years with fasting lipoprotein profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride).  |   |  |  |   |  |  |
| Diabetes (Type 2)   | Screen every 3 years beginning at age 45. Screen more often and beginning at a younger age for those who are overweight and if risk factors are present.         |   |  |  |   |  |  |
| Infectious Disease Scre   | ening  |   |  |  |   |  |  |
| Sexually Transmitted<br>Infections (Chlamydia,<br>Gonorrhea, Syphilis, and<br>HPV)  | For chlamydia and gonorrhe   |   | der age 25: Screen annually. F<br>d not previously vaccinated, c   |  |   |  |  |
| HIV   | Routine/annual testing of all patients at increased risk. Starting at age 13, CDC recommends universal screening.  |   |  |  |   |  |  |
| Hepatitis C   | Periodic testing of all patient  | s at high risk.                               |  |  |   |  |  |
| Tuberculosis (TB)   | Tuberculin skin testing of all   | patients at high risk.                        |  |  |   |  |  |
| Sensory Screening   |  |   |  |  |   |  |  |
| Eye Exam for Glaucoma   | At least once for patients wit years in high-risk patients.  | h no risk factors. Every 3-5                  | Every 2-4 years.   | Every 2-4 years.   | Every 1-2 years.  |  |  |
| Hearing and Vision<br>Assessment  | Ask about hearing and vision impairment, and counsel about the availability of treatment when appropriate.   |   |  |  |   |  |  |



## **2010/11 Adult Preventive Care Recommendations**

## **General Counseling**

All patients should be periodically screened and counseled as appropriate regarding: depression/suicide, alcohol/substance abuse, tobacco, diet/nutrition, obesity and eating disorders, preconception counseling, physical activity, infectious diseases/STIs, safety/injury and violence prevention, family violence/abuse, skin cancer, menopause management, osteoporosis, and dementia/cognitive impairment.

| 2010 Immunization<br>Schedule                | 18-29 Years   | 30-39 Years   | 40–49 Years | 50-64 Years  | 65 + Years              |  |  |  |
|--|---|---|-------------|--|-------------------------|--|--|--|
| Tetanus, Diphtheria,<br>Pertussis (Td/Tdap)  | For adults < 65 years of age<br>Td booster every 10 years. For<br>replace a single dose of Td.  | For adults ≥ 65 years of age: 3 doses of Td if not previously immunized. Td booster every 10 years                    |             |  |                         |  |  |  |
| Human papillomavirus<br>(HPV)                | 3 doses for unvaccinated female adults aged ≤ 26 years.   |   |             |  |                         |  |  |  |
| Measles, Mumps, and<br>Rubella (MMR)         | ≥ 1 dose if born ≥ 1957 and evidence of immunity to me 2 doses, second dose ≥4 we 2) previously vaccinated wit of vaccine 1963-1967; 4) stucare setting; or 6) plan to tra  | < 1957: 1 dose  |             |  |                         |  |  |  |
| Varicella (Chicken Pox)                      | 2 doses administered 4-8 weeks apart, if not previously immunized and no history of chicken pox or shingles, or if at high risk.  |   |             |  |                         |  |  |  |
| Influenza                                    | 1 dose annually for all adults  |   |             |  |                         |  |  |  |
| Pneumococcal<br>(Polysaccharide)             | 1 dose if at risk and not prev<br>nephrotic syndrome; asplen  | 1 dose after 65 years of age, even if vaccinated before 65 years of age.  |             |  |                         |  |  |  |
| Hepatitis B                                  | 3 doses if at risk and not pre  |   |             |  |                         |  |  |  |
| Hepatitis A                                  | 2 doses if at risk and not pre  |   |             |  |                         |  |  |  |
| Meningococcal<br>Conjugate Vaccine<br>(MCV4) | 1 dose for: 1) college freshmen living in dormitories; 2) laboratory workers routinely exposed to Neisseria meningitidis; 3) adults with asplenia or terminal complement component deficiency; 4) military recruits; 5) travelers to sub-Saharan Africa (Dec –Jun), or to Mecca during annual Hajj. Consider for persons with HIV.  Revaccination 3-5 years after first dose may be indicated for adults previously vaccinated with MPSV4 who remain at risk. Currently, only a single dose of MCV4 is recommended. The need for boosters after a dose of MCV4 has not been determined. |   |             |  |                         |  |  |  |
| Meningococcal<br>Polysaccharide (MPSV4)      | Adults ≤ 55 years of age: MC  | dults ≤ 55 years of age: MCV4 preferred, MPSV4 acceptable.  Adults > 55 years of age: MPS product for this age group. |             |  |                         |  |  |  |
| Zoster                                       |   |   |             | 1 dose for all adults aged ≥ 6 history of herpes zoster. | 50 years, regardless of |  |  |  |

Oct. 2010 This summary represents a compilation of evidence-based recommendations from national agencies, reviewed by a collaborative working group of clinicians and endorsed by leading health care organizations in Massachusetts. These guidelines are intended as quality practice recommendations. They are not intended as a description of benefits, conditions of payment, or any other legal requirements of any particular health plan or payor. Each health plan or payor makes its own determination of coverage and benefits. In the event that these practice recommendations are inconsistent with any applicable laws or regulations, such laws or regulations take precedence.

We acknowledge the efforts of the Publications Unit in the Office of MassHealth Operations for design and editorial assistance.